Hypercalcaemia in Malignancy

Author: Andrew Parfitt, Shumontha Dev / Editors: Adrian Boyle / Reviewer: Shanthi Siva, Emma Everitt / Codes: O6, O7 / Published: 20/05/2021


Hypercalcaemia is commonly seen in patients with malignant disease. This session explains the assessment and management of the problem in the emergency department.

By the end of this session you will be able to:

  • Describe symptoms and signs of hypercalcaemia in malignancy
  • Interpret serum calcium results
  • Describe how to respond to hypercalcaemia in an emergency situation
  • Explain the ongoing management of hypercalcaemia in oncology patients


  1. Hemphill R R. Hypercalcaemia. www.emedicine.com. 2007
  2. Bilezikian J P. Management of acute hypercalcaemia. N Engl J Med. 1992; 326: 1196-1203
  3. Claudius I A. Hypercalcaemia. www.emedicine.com 2006
  4. Longmore M, Wilkinson I et al. Oxford handbook of Clinical Medicine 7th Edition. Oxford University Press 2007; page 138
  5. Fraser Health. Hypercalcaemia in malignant disease (palliative management). Hospice Palliative Care, Clinical Practice Committee 2006
  6. Palmer E and Howarth J. Hypercalcaemia. Palliative Care for the Primary Health Care Team, Quay Books 2004; pages 140-152
  7. Ma J O, Cline D M, Tintinalli J E, et al. Emergency Medicine Manual 6th Edition. American College of Emergency Physicians and McGraw Hill 2004; pages 1341-1368
  8. Hutton E. Evaluation and management of hypercalcaemia. JAAPA 2005; 18(6): 30-35.
  9. Ralston S H. Medical management of hypercalcaemia. Br. J. Clin. Pharmac 1992; 34: 11-20
  10. Kinirons M T. Newer agents for the treatment of malignant hypercalcaemia. Am J Med Sci 1993; 305(6): 403-6
  11. Stewart A F. Clinical practice: Hypercalcaemia associated with cancer. N Engl J Med, 2005; 352(4): 373-9
  12. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol. 2002 Dec;29(6 Suppl 21):12-8.
  13. Nussbaum SR, Younger J, et al., Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993; 95(3): 297-304.
  14. Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet. 1985; 2(8461): 907-10.
  15. Hotte S.J. Hirte H.W. Rabbani S.A.,Carling T. Hendy G.N. Hypercalcaemia of Malignancy: Pathophysiology Diagnosis and Treatment American Journal of Cancer 2002; 1(3): 179-187(9)
  16. Major P Lortholary A Hon J, Zoledronic Acid is superior to pamidronate in the treatment of hypercalcaemia of malignancy: A pooled analysis of 2 randomised controlled clinical trials. Journal Clinical Oncology. 2001; 19: 558-567
  17. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol. 1992; 10: 134-42
  18. Evidence 1 – Hypercalcemia of malignancy: Mechanisms , Author Mara J Horwitz, MD, Uptodate.com
  19. Evidence 2 – Mirrakhimov AE. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. North American Journal of Medical Sciences. 2015;7(11):483-493. doi:10.4103/1947-2714.170600.
  20. Evidence 3 – LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med. 2008 Aug 19;149(4):259-63.
  21. Evidence 4 – Sandler L M, Winearls C G, Studies of the Hypercalcaemia of Sarcoidosis: Effect of Steroids and Exogenous Vitamin D3 on the Circulating Concentrations of 1, 25-Dihydroxy Vitamin D3, QJM: An International Journal of Medicine, Volume 53, Issue 2, SPRING 1984, Pages 165180.

Leave a Reply